Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CTLA-4 blockade: autoimmunity as treatment.

× No keyword cloud information.

8 in total

Review 1. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.

Authors: James L Gulley; Charles G Drake
Journal: Clin Cancer Res Date: 2011-06-15 Impact factor: 12.531

2. Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy.

Authors: Farideh Hosseinzadeh; Saeed Mohammadi; Foroogh Nejatollahi
Journal: Rep Biochem Mol Biol Date: 2017-10

3. Immunotherapy for advanced prostate cancer.

Authors: Johannes Vieweg
Journal: Rev Urol Date: 2007

4. [Immunotherapy for metastatic prostate cancer: do we really need this?].

Authors: A Heidenreich
Journal: Urologe A Date: 2012-01 Impact factor: 0.639

5. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Authors: F Stephen Hodi; Marcus Butler; Darryl A Oble; Michael V Seiden; Frank G Haluska; Andrea Kruse; Suzanne Macrae; Marybeth Nelson; Christine Canning; Israel Lowy; Alan Korman; David Lautz; Sara Russell; Michael T Jaklitsch; Nikhil Ramaiya; Teresa C Chen; Donna Neuberg; James P Allison; Martin C Mihm; Glenn Dranoff
Journal: Proc Natl Acad Sci U S A Date: 2008-02-19 Impact factor: 11.205

CTLA-4 blockade: autoimmunity as treatment.

Review 1. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.

2. Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy.

3. Immunotherapy for advanced prostate cancer.

4. [Immunotherapy for metastatic prostate cancer: do we really need this?].

5. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

6. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

7. Anti-CD40 agonist antibodies: preclinical and clinical experience.

Review 8. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.